AMR Stakeholder Profile
Focus area/active in: Therapeutics
Company/Organisation type: Accelerator | Finance | Investor
In its 2017 European One Health Action Plan against AMR, the European Commission included a chapter dedicated to boosting research, development and innovation which cites the Innovative Medicines Initiative (IMI) as one of the tools to be used to address AMR. IMI launched the AMR Accelerator programme in 2019 as part of IMI2 – Call 15 and 16. The goal of the AMR Accelerator is to progress the development of new medicines to treat or even prevent resistant bacterial infections in Europe and worldwide. The AMR Accelerator comprises three pillars: A Capability Building Network (the COMBINE project) will coordinate the programme and carry out research to strengthen the scientific basis in the AMR field, while the Tuberculosis Drug Development Network (the ERA4TB project) will work to accelerate the discovery of new combinations of drugs to treat TB. Finally, Portfolio Building Networks (the RespiriTB, RespiriNTM, TRIC-TB, GNA NOW and AB-Direct projects) will support collaborative efforts to discover, develop and advance new and innovative agents to prevent or treat AMR.
See our flyer for more details:
Call for preclinical and clinical data sets from the study of prevention or treatment of bacterial infections
Would you like to meet the AMR Accelerator virtually during the AMR Conference week?
Get in touch!
Prof. Dr. Anders Karlén, Uppsala University
Please fill out the form below to get in touch with us.